Neurological malignancies in neurofibromatosis type 1. Issue 6 (November 2019)

• Record Type: Journal Article
• Authors: Eoli, Marica; Saletti, Veronica; Finocchiaro, Gaetano
• Is Part Of: Current opinion in oncology. Volume 31:Issue 6(2019:Nov.)
• Publication Date: 2019-11
• Subjects: genetic profiling -- glioma -- malignant peripheral nerve sheath tumor -- neurofibroma -- neurofibromatosis 1; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000576
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: The current review summarizes recent advances on three important issues in neurofibromatosis type 1 (NF1) management: the identification of specific NF1 gene mutations predicting the risk for developing neurological malignancies; the molecular features of NF1-associated tumors and their differences from sporadic neoplasms; genetic, epigenetic, or microenviromental factors leading benign tumors to a malignant transformation in NF1. Recent findings: The association between the risk of developing optic pathway glioma and specific germiline NF1 mutations is still debated and further studies are needed with large, new cohorts of patients. The available evidences suggest that gliomas and malignant peripheral nerve sheath tumors (MPNSTs) in NF1 have a distinct genetic signatures, different from those observed in sporadic neoplasms. Some neoplasms, very rare in general population, such as subependymal giant cell astrocytoma, can be observed in NF1. A subgroup of low-grade NF1-gliomas, some MPNSTs and plexiform neurofibromas contain abundant T lymphocyte infiltrates suggesting that immunotherapy could be a potential therapeutic approach. Summary: These data support the notion that next-generation sequencing efforts are helpful in the genetic characterization of NF1-associated malignancies A better knowledge of those tumors at the genomic level, is essential for addressing new treatments and may contribute to a deeper comprehension of NF1/RAS signaling also in sporadic cancers.